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Introduction
Pregnancy, specifically human gestation, begins even before the 
release of a mature oocyte and ends with parturition, approxi-
mately 9 months later. Pregnancy is an amazing phenomenon that 
integrates many complex physiological processes and ultimately 
results in reproduction of the human species. During this vital 
time the placenta is formed as a transient organ, and it continues 
to play a critical role in maintaining the health of both the embryo/
fetus and the mother up until the time of delivery. It continuously 
evolves to meet the changing needs of the developing fetus within 
its maternal physiological environment (Linzer and Fisher, 1999). 
The placenta has two major functions. The first function is the 
exchange of metabolic and gaseous products between maternal 
and fetal bloodstreams. In this way the placenta is able to pro-
vide oxygen and nutrients, as well as remove waste products for 
the developing fetus. The second function is hormone production 
(Linzer and Fisher, 1999). The hormones produced and released 
by the placenta assist in triggering the maternal physiological 
changes necessary to meet the needs of the fetus, as well as the 
changes needed to prepare the mother for the specific needs of 
the baby after birth. These changes are widespread amongst the 
various systems of the mother and are coordinated largely by cir-
culating hormones. Some of these hormones are hormones that 
are commonly found circulating within the adult (non-pregnant) 
female in various concentrations. Others are hormones unique 
to the pregnant female only and are not otherwise found in the 
body. This role makes the placenta an important endocrine organ 
necessary for the successful continuation of a pregnancy (Sadler, 
2012) (Linzer and Fisher, 1999).
Background
In order to understand how the placenta functions, it is important 
to first understand how it is formed, beginning with fertilization. 
During ovulation, one mature oocyte is usually released by the 
ovaries and is transported into the uterine tube by the sweeping 
action of tubal fimbriae. When all biological conditions are suit-
able, and if a sperm meets the released egg, then fertilization of the 
embryo generally takes place in the fallopian tubes. The fertilized 
egg then goes through a series of cell divisions eventually creating 
a tightly grouped ball of sixteen cells called a morula. On approxi-
mately the third or fourth day after fertilization the morula begins 
to travel down the fallopian tube, eventually reaching the uterus. 
A fluid filled cavity begins to appear within the morula, and it de-
velops into a blastocyst. The inner cell mass of the blastocyst will 
form the embryoblast, which gives rise to tissues of the embryo 
proper, and the rest of the cell mass, which surrounds the inner 
cells and blastocyst cavity, will form the trophoblast, which later 
contributes to the placenta (Sadler, 2012).
By this time, the zona pellucida, which is the glycoprotein mem-
brane that surrounded the ovum, has disappeared and implanta-
tion into the uterus begins as the blastocyst continues to evolve. 
This occurs on the sixth day after fertilization, as trophoblastic 
cells begin to penetrate between the epithelial cells of the uter-
ine mucosa (Sadler, 2012). At this time, the mucosa of the uterus 
is in the secretory phase of the menstrual cycle, in response to 
progesterone that is released by the corpus luteum that remains 
following ovulation. The corpus luteum is maintained for the first 
few weeks of pregnancy by the release of hCG from the tropho-
blast and it continues to release specific hormones that affect the 
uterus and allow implantation to occur. Eventually, however, the 
corpus luteum degenerates and is replaced by the placenta, which 
then becomes responsible for continued hormone production 
(Cole, 2012). 
In preparation for implantation, the glands and arteries of the 
uterine endometrium become coiled and three distinct layers 
form in the endometrium. The formation of the placenta then re-
sults from mutual interaction of the trophoblast and the endome-
trium. Under normal circumstances, the blastocyst implants along 
the anterior or posterior wall of uterine endometrium, where 
it becomes embedded between the openings of the glands and 
continues to root itself more deeply into the endometrium until 
it becomes completely embedded and almost entirely covers the 
uterine wall, on approximately the eleventh or twelfth day. (Sadler, 
2012).
At the time of implantation the development of the placenta be-
gins, as the trophoblast continues to develop by differentiating in 
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to two layers. These layers include the cytotrophoblast and the 
syncytiotrophoblast (Carlson, 2004). The cytotrophobast, which 
is the inner layer, consists of mononucleated cells that migrate 
and fuse to form a multinucleated syncytiotrophoblast, which will 
function as the endocrine unit of the placenta (Alsat et. al. 1997). 
The syncytiotrophoblast, which is a highly invasive tissue, soon 
surrounds the entire blastocyst and begins to insert small pro-
jections between uterine epithelial cells. It continues to spread 
towards the basal lamina underlying the endometrium, forming 
a flattened trophoblastic plate, eventually eroding maternal tis-
sue, actually penetrating the basal lamina, and making its way into 
the endometrial stroma. During this time, isolated vesicles, called 
lacunae form in the trophoblast, and as the syncytiotrophoblast 
erodes maternal vessel walls, maternal blood begins to fill the 
lacunae. As this process continues, and as maternal blood flows 
through the trophoblastic system, a basis for utero-placental cir-
culation is established (Carlson, 2004).
As the trophoblast continues to grow and develop, so does the 
embryoblast, as it differentiates into two layers. A thin membrane 
then lines the inner surface of the cytotrophoblast, forming the 
exocoelomic cavity or the primitive yolk sac. A new layer of cells 
appears between the trophoblast and this membrane, and forms 
a matrix of loose connective tissue known as the extraembryonic 
mesoderm. It lies immediately internal to the entire trophoblast, 
as well as around the layers of the embryoblast (including the yolk 
sac and amniotic cavity). Cavities soon develop and then merge to 
form a single large cavity that surrounds the yolk sac and amni-
otic cavity. This cavity is the chorionic cavity. The chorionic plate 
encompasses the part of the extraembryonic mesoderm that 
borders the fetal side of the placenta, along with its trophoblast. 
The connective stalk is then the only place where the chorionic 
plate traverses through chorionic cavity. With the development of 
blood vessels as well as other elements, the connective stalk be-
comes the umbilical cord which will form the connection between 
placenta and embryo (Sadler, 2012). 
By the beginning of the third week, the cells of the cytotropho-
blast, which continue to proliferate towards the endometrium, 
eventually penetrate the syncytiotrophoblast and form col-
umn-like structures that are surrounded by a syncytial layer. These 
are the primary villi. Mesodermal cells then penetrate the core of 
the primary villi to form secondary villi. Mesodermal cells then 
differentiate into blood cells and blood vessels, forming a capil-
lary network that makes contact with capillaries developing in the 
chorionic plate, the connecting stalk, and eventually the intraem-
bryonic circulatory system. The villous system is getting ready for 
the time that the heart begins to beat, at approximately the fourth 
week of development (Sadler, 2012).
The villi on the embryonic pole continue to grow and develop, giv-
ing rise to the chorion frondosum, which is a bushy chorion area, 
while the villi on abembryonic pole eventually degenerate. The 
portion of the endometrium that lies over the embryonic pole 
becomes abundant with lipids and glycogen and becomes firmly 
attached to the chorion. This is the decidua basalis. The remaining 
portion of the endometrium that lies over the abembryonic pole 
also degenerates. Together, the chorion and the decidua basalis 
make up the placenta, which becomes the only portion of the 
chorion where the exchange of maternal and fetal materials takes 
place. Maternal blood from the lacunae of the syncytiotrophoblast 
begins to fill the intervilli spaces of the chorion. Septa continue to 
form from the decidua, protruding into intervilli space, but never 
actually reaching the chorion. This, in turn, forms compartment-like 
structures, called cotyledons, that are not fully separated by the 
septa. It is in these compartments that high pressure arteries bring 
oxygen-rich blood towards the villous trees that have developed 
in the chorion and then back towards endometrial veins. The in-
tervillous spaces of a mature placenta contain approximately 150 
mL of blood, which is replenished about 3-4 times per minute. 
At all times there is a layer of syncytium that separates maternal 
blood from fetal tissue, as part of the placental membrane.  The 
villi serve to increase surface area and are the primary site of 
placental exchange (Sadler, 2012). 
As the pregnancy progresses, the placenta continues to grow, cov-
ering approximately fifteen to thirty percent of the internal surface 
of the uterus (Carlson, 2004). This growth serves to accommodate 
the ever growing needs and demands of the developing fetus and 
ensures sufficient transfer of nutrients. Continuous proliferation, 
differentiation, and fusion of cytotrophblast is what maintains and 
expands this syncytial interface throughout pregnancy as syncy-
tiotrophblast cells are shed into maternal circulation when they 
reach the end of their life cycle (Forbes and Westwood, 2010).  A 
clear relationship has been established, with a direct relationship 
between placental weight and fetal weight throughout pregnancy. 
This points to the ever important role that the placenta unit plays 
in fetal growth, through its various functions (Alsat et. al. 1997).
One major function of the placenta at this point, as mentioned, 
is the exchange of nutrients and wastes. Through the process of 
diffusion, gases, such as oxygen, carbon dioxide, and carbon mon-
oxide are exchanged between mother and fetus. Additionally, the 
exchange of nutrients and electrolytes, such as amino acids, fatty 
acids, carbohydrates, and vitamins are also diffused through the 
placental barrier. Although immunity is beginning to develop, ma-
ternal antibodies are also transported from the mother to the 
fetus via the placenta (DeChemey et. al. 2013).
The seconds major function of the placenta is the production of 
hormones which serve to maintain the pregnancy, to uphold an 
optimal environment within the physiology of the mother, and to 
prepare the mother for birth. The release of hormones by the 
placenta is an endocrine communication system that stimulates 
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specific reactions on target tissue, facilitating changes necessary 
for the state of the pregnancy. The myometrium, which lies just 
beneath the endometrium is a vital tissue during the pregnancy 
period, and it is a critical target for fetal placental communication. 
The major hormone changes that occur through these placental 
communications are noted specifically in the increased levels of 
estrogen, progesterone, and chorionic gonadotropin. However, 
there are other hormones as well, that participate in this complex 
system of fetal-maternal interaction, although on a smaller scale, 
(DeChemey et. al. 2013).
Steroid Hormones
Over the years much research has been done in order to de-
termine the actual role of the placenta in hormone production. 
One group of hormones produced by the placenta are the steroid 
hormones estrogen and progesterone. Various studies have been 
done to verify that it is actually the placenta that produces the 
elevated levels of these hormones during pregnancy. Studies in 
which pregnant women underwent surgery to remove the corpus 
luteum at various stages of pregnancy resulted in a substantial 
amount of lost pregnancies when the corpus luteum was removed 
before the eighth week. Removal of the corpus luteum after the 
eighth week did not result in abortions. These results suggest that 
after the eight week there are a significant amount of placental 
secretions (Csapo et. al. 1972). Furthermore, women with ovarian 
failure who participated in an ovarian assisted reproduction pro-
gram demonstrated increased peripheral blood progesterone and 
estradiol levels by the fifth week of pregnancy. These levels were 
above the background levels achieved by the constant replace-
ment regimen. With the absence of ovarian function, this study 
also suggests the role of the placenta in maintaining proper hor-
mone levels and sustaining pregnancy (Scott et. al. 1991). 
Estrogen
Estrogen is a steroid hormone that is produced in the syncytiotro-
phoblast of the placenta (Alsat et. al. 1997), with the placenta be-
coming the primary source of this hormone approximately during 
the ninth week of pregnancy. Estrogen levels remain low during 
the first trimester of pregnancy and then progressively increases, 
remaining elevated, until labor. 
An important role of estrogen during pregnancy is the synthesis 
of contractile proteins in the myometrium, as well as local concen-
tration of contraction associated proteins, such as oxytocin and 
connexin-43 (Cx-43). It also increases prostaglandin production 
and regulates the expression of nitrate oxide synthase isoforms. 
Estrogen, therefore, plays a significant role in preparing the uterus 
for labor contractions and delivering the baby. Although estrogen 
assists in the priming of the myometrium for labor, it is important 
to note that the estrogen alone is not clinically effective in the 
induction of labor. Furthermore, a pregnancy can continue to exist 
and labor is still possible, even amongst women with low levels 
of circulating estrogen (Ticconi et. al. 2006). However, in cases of 
low placental estrogen synthesis, changes that generally occur in 
the reproductive tract before parturition, such the ripening of the 
cervix, generally do not occur (Strauss et. al. 1996). The actions of 
estrogen are therefore efficient in conjunction with other factors 
(Ticconi et. al. 2006).
Other significant functions of estrogen are the stimulation of uter-
ine growth, as well as development of the mammary glands, in 
preparation for birth. The development of the mammary gland be-
gins initially at puberty with estrogen exposure and is completed 
in the third trimester of pregnancy (Sadler, 2012). 
Progesterone
Progesterone is another major steroid hormone that is produced 
by the placenta. Until approximately ten weeks gestation, pro-
gesterone is produced by the corpus luteum that remains after 
ovulation. In a normal menstrual cycle where pregnancy does 
not occur, the corpus luteum degenerates soon after ovulation. 
However, when pregnancy does occur, hCG that is released from 
the trophoblast stimulates the maintenance of the corpus luteum, 
which, in turn, releases progesterone. This prevents the shedding 
of the endometrium lining (Cole, 2012) and allows for proper 
implantation (Kumar and Magon, 2012). Progesterone continues 
to be released by the corpus luteum until approximately week 
eight to ten gestation. It then continues to be produced by the 
placenta, specifically by the syncytiotrophoblasts of the chorion, in 
response to the uptake of maternal lipoproteins. The expression 
of low density lipoproteins appears to be directly related to the 
presence of progesterone (Ticconi et. al. 2006).
Progesterone acts in multiple ways to decrease the contractility of 
the myometrium lining of the uterus. By decreasing Cx-43 expres-
sion, stimulating nitrate oxide expression, and down-regulating 
calcium channels and oxytocin receptors, progesterone serves to 
maintain a state of dormancy during most of the pregnancy. Three 
progesterone receptor subtypes, PR-A, PR-B, and PR-C have been 
identified. Only PR-B mediates the expression of progesterone re-
sponsive genes, whereas PR-A represses this activity. During most 
of pregnancy, PR-A levels are low. At the time of labor, however, 
PR-A levels increase drastically, as do PR-A receptors, thereby 
suppressing the effects of placental progesterone during this cru-
cial time and allowing uterine contractions to progress, despite 
maternal circulating progesterone (Ticconi et. al. 2006).
Although progesterone has a quiescent effect on the uterus, an-
other primary function of this hormone is its effect on the cer-
vix. Progesterone has been found to have a direct effect on the 
length of cervix, and in this way serves to prevent preterm labor. 
Studies have shown that a shortened cervix in the second trimes-
ter is often an early indicator that preterm labor will occur. Both 
natural and synthetic progesterone have been found to have a 
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strengthening and lengthening effect on the cervix, and are there-
by often effective in postponing preterm labor. Local withdrawal 
of progesterone at the cervical level appears to have the opposite 
effect of softening and effacing the cervix in preparation for deliv-
ery. Although exact mechanisms are unknown at this time, proges-
terone has been shown to have an effect on mucus plug formation 
and possibly contributes to improved antimicrobial activity in this 
area (Campbell, 2011). 
Another important function of progesterone is its contribution 
to mammary gland development. Although the mammary glands 
begin to develop at puberty, continued development and prepara-
tion for lactation is still necessary. Progesterone had been found 
to be associated with ductal proliferation and lobuloalveolar dif-
ferentiation. This enables the mammary glands to produce and 
secrete milk after delivery (Lydon et. al 2000).
Peptide Hormones
Human Chorionic Gonadotrophin
Human Chorionic Gonadotrophin (hCG) is a pregnancy hormone 
that is critical to both the establishment and maintenance of the 
pregnancy, playing a role in multiple facets of the pregnancy pro-
cess. HCG is a glycoprotein hormone that is similar in structure 
to luteinizing hormone (LH). It is synthesized and secreted pri-
marily by the syncytiotrophoblasts, and it binds to specific hCG 
receptors in target tissues (Ticconi et. al. 2007). It is detectable 
early in pregnancy, as soon as eight to nine days after ovulation 
and levels continue to rise until the final weeks of pregnancy. 
Emerging evidence continues to demonstrate a wider range of 
biological effects that hCG has on various tissues types than was 
previously recognized.
One of the major functions of hCG during the first trimester 
is the prevention of luteolysis and stimulation of progesterone 
production in the corpus luteum (Cole, 2012). As mentioned, this 
ensures that the uterus, which is generally in the secretory stage 
of the menstrual cycle at the point of fertilization, maintains an 
optimal state for implantation to occur (Ticconi et. al. 2007). By 
sustaining the production of progesterone, hCG indirectly works 
to maintain the decidual cells of the endometrium, thereby pre-
venting aptosis. At this point, hCG also functions to promote 
angiogenesis in the uterine vasculature, allowing for improved 
circulation and maximum blood supply to the area as the placenta 
forms. HCG has also been shown to control growth and develop-
ment of the umbilical cord in this way (Cole, 2012). HCG, which 
is considered to be similar to thyroid stimulating hormone (TSH), 
mildly stimulates the thyroid gland to produce more thyroid hor-
mone throughout pregnancy. This is especially important, as the 
thyroid hormone passes through the placenta and is critical for 
brain and nervous system development in the fetus. At approxi-
mately twelve weeks, the fetus begins to produce its own thyroid 
hormone (Kilby et. al. 2005).
After the first trimester, hCG continues to play a pivotal role in 
maintaining the pregnancy through various mechanisms.  Studies 
have shown that hCG strongly induces the proliferation of myo-
metrial smooth muscle cells. This contributes to the continuous 
growth of the uterus throughout pregnancy, providing an optimal 
environment for the simultaneous continuous growth and devel-
opment of the fetus. HCG also assists in inhibition of uterine con-
tractility. Just like progesterone, HCG has been found to directly 
decrease expression of connexin 43. It has also been found to 
reduce the expression of PR-A, further reducing uterine contrac-
tility in this way. HCG also decreases intracellular concentration 
of free calcium in the smooth muscle cells, thereby inhibiting 
the amplitude of response to oxcytocin-stimulated contractions. 
Additionally, hCG is the only pregnancy hormone that has been 
found to inhibit the expression of phosphodiesterase (PDE) 5 en-
zyme, which is involved in the hydrolysis of cAMP and cGMP that 
regulate myometrial relaxation.  This further assists in modulating 
uterine contractility and in inhibition of preterm labor (Ticonni et. 
al. 2007). During the final weeks of pregnancy, levels of hCG tend 
to drop, in preparation for delivery. This drop allows for increased 
responsivity to prostaglandin and oxytocin, enabling contractions 
to occur (Ticonni et. al. 2006).
Another important function of HCG is its effect on the fetal mem-
branes. A study conducted by Ticconi et al (2007) demonstrated 
increased expression of the isoform of nitric oxide synthase in 
response to hCG. This, in turn, may contribute to the relaxed state 
of the uterus as well as to immune system activity in the fetal 
membranes, although this has not yet been proven (Ticconi et. 
al. 2007). Additionally, hCG promotes anti-macrophage inhibitory 
factor, thereby preventing rejection of the foreign fetal tissue by 
the mother throughout pregnancy (Cole, 2012). Additionally, new 
studies have found hCG receptors in many fetal organs and tissues. 
This may indicate that hCG also plays a role in fetal growth during 
pregnancy. These receptors are then removed upon partuition. It 
is also interesting to note the hCG receptors are also found in 
the hippocampus, hypothalamus, and brain stem of the mother. 
This may explain the presence of nausea and vomiting that often 
occurs in pregnancy, as receptors detect this hormone in maternal 
circulation (Cole, 2012).
Another form of hCG is the sub-type hyperglycosylated hCG. 
Although it is an autocrine, and not a hormone, hyperglycosylated 
hCG promotes cytotrophobast cell growth during the early stages 
of pregnancy. HCG then promotes the fusion and differentiation 
of these cells to syncytiotrophoblast cells, leading to the forma-
tion of the villous system. This, combined with angiogenesis and 
umbilical cord formation, becomes the fetal maternal interface of 




Chorionic somatomammotrophin (hCS), also known as placental 
lactogen hormone (LH) is a lactogenic protein that is also pro-
duced by the syncytiotrophoblasts of the placenta (Ayala et. al. 
1989). It is considered to be similar, immunologically, to pituitary 
growth hormone, and it effects fetal growth in an indirect man-
ner, according to present studies. It is secreted almost exclusively 
into maternal circulation, with only small amounts crossing into 
fetal circulation. It can first be detected in the maternal blood 
stream at approximately six weeks gestation, and it plays a signifi-
cant role in maternal metabolism, as maternal hCS concentrations 
tend to rise throughout pregnancy with irregular fluctuations 
(Handwerger and Freemark, 1987). During approximately the last 
month of pregnancy, hCS levels usually level off. It has been found 
that depressed levels of maternal hCS correlate with intrauterine 
growth retardation and are associated with high risk pregnan-
cies. It should also be noted that levels of hCS have been noted 
to increase in direct proportion to increased placental volume 
(Macmillan et. al. 1976).
HCS works in a manner that is similar to human growth hormone 
(hGH). It works to effect both carbohydrate and protein metabo-
lism in the mother. Like hGH, hCS enhances insulin secretion and 
impairs glucose tolerance in the mother, thereby facilitating and 
increasing the supply of glucose and energy that is available to be 
delivered to the fetus. HCS also facilitates an increase in lipolysis 
in adipose tissue of the mother. This helps to ensure that more 
free fatty acids are available for energy use by the mother instead 
of glucose. In this way even more glucose is available for use by 
the fetus. Furthermore, ketones that are formed from the free 
fatty acids can cross the placenta and can be used by the fetus. 
Large amounts of hCS released from the second month of preg-
nancy onward appear to be related to breast, nipple, and alveolar 
growth, although exact mechanisms are uncertain (Handwerger 
and Freemar, 1987).
Placental Growth Hormone
During the early stages of pregnancy, until approximately 20 weeks, 
pituitary growth hormone (GH), which originates in the pituitary 
gland of the mother, is the primary growth hormone found in 
maternal circulation. Then, from approximately twelve to twenty 
weeks, until term, placental growth hormone gradually replaces 
pituitary growth hormone, which eventually becomes undetect-
able in maternal circulation. Placenta growth hormone is similar 
in structure to pituitary growth hormone, but is produced in the 
syncytiotrophoblasts of the placenta. Additionally, it binds to cell 
receptors with similar affinity to pituitary GH. PGH has a relative-
ly short half-life and there is a rapid fall in serum concentrations 
within one hour after removal of the placenta following delivery 
(Lacroix et. al. 2002). 
Placental GH is secreted in a continuous, non-pulsatile fashion 
into maternal circulation only and is not detected in fetal blood 
at all. This continuous secretion of placental GH into maternal 
circulation has critical implications for maternal physiological ad-
aptation to gestation, as it impacts metabolism. Although it does 
not have a direct impact on fetal growth, this hormone works to 
stimulate gluconeogenesis, lipolysis, and anabolism in the liver and 
other organs of the mother. In this way it serves to increase nutri-
ent availability for the fetal-placental unit, indirectly affecting fetal 
growth. This is especially important during the last few months of 
pregnancy when fetal growth is most prominent. Furthermore, 
intrauterine growth restriction has been found to be associated 
with decreased levels of placental GH, indicating the crucial role 
this hormone plays for the developing fetus. Both the rate of syn-
thesis, as well as maternal blood levels of this hormone, have been 
found to be directly related to growth of the placenta (Lacroix et. 
2002,) (Alsat et. al. 1997).
Placental GH demonstrates high somatogenic activity, and just like 
pituitary GH, it has been found to induce weight gain. It has also 
been found to be one of the key regulators of maternal Insulin Like 
Growth Factor 1 (IGF1). Additionally, placental GH concentration 
has been found to decrease in response to high levels of glucose. 
As the syncytiotrophoblast, which regulates the expression of 
Glut1, a major glucose transporter, comes into direct contact 
with maternal blood circulation, elevated glucose levels may be 
detected by these cells. The sycncitiontrophoblast then respond 
to variations in maternal blood glucose by modifying placental GH 
secretion. Recent data on the expression of placenta GH and its 
receptors in the villi of the trophoblast open new questions as to 
other roles that this hormone may play (Lacroix et. al. 2002).
Insulin-Like Growth Factor
The presence of various growth factors (GF) in maternal circu-
lation is generally increased throughout gestation and specific 
growth factors, such as insulin-like growth factor (IGF), have been 
found to be linked to fetal growth. Two specific IGF types, IGF 1 
and IGF 2 have been identified, and both have been found to be 
positively correlated to fetal birth weight (Forbes and Westwood, 
2010). These peptide hormones work by binding to specific re-
ceptors on target tissues in order to mediate a variety of met-
abolic and mitogenic processes. Although IGF 1 and IGF 2 each 
have individual receptors, both typically bind to IGF 1 receptor 
(IGF1R) through the aid of binding proteins. This receptor is found 
in all cell types of the placenta, including trophoblast, villous en-
dothelium, and mesenchymal cells and is thought to regulate the 
mitogenic effects of IGF 1 and IGF 2. IGF binding proteins that are 
generally found in abundance in the area of the placenta are also 
correlated to fetal growth (Hiden et. al. 2009).
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Although exact mechanisms remain unclear, it appears that one 
way in which IGFs affects fetal growth is through its effect on the 
placenta. Placentally derived IGF2 have been found to have a role 
in promoting trophoblast invasion, thereby promoting placental 
growth and function. Studies have also shown that exposure of 
the syncytial surface to IGFs enhanced cytotrophoblast prolifera-
tion and differentiation. Because placenta growth has been closely 
associated with fetal growth, continuous proliferation of cytotro-
phblast cells in order to maintain the placenta is crucial. By stimu-
lating placental growth, IGF works to enhance nutrient transport 
and delivery to the fetus, thereby promoting fetal growth (Forbes 
and Westwood, 2010)
Vascular Endothelial Growth Factor
Vascular endothelial growth factor (VEGF) is an essential hor-
mone for placental growth, and it has a significant impact on 
coordinating angiogenesis, blood flow, and the breakdown of the 
extracellular matrix in the placenta. It is found to be present in 
the blood vessels of both placenta and the umbilical cord, and it is 
hypothesized that it acts as a paracrine hormone on fetoplacental 
circulation. In this way it contributes to the growth and mainte-
nance of the placenta as well as delivery of oxygen and nutrients 
to the fetus. This hormone further assists in vasodilation, as there 
is no sympathetic innervation in the spiral arteries and in the pla-
centa. These functions are vital for the growth and development of 
the fetus, as adequate nutrient supply is crucial. Studies have noted 
a decreased vascular response to VEGF in cases of intrauterine 
growth retardation. This indicates the importance of the effects of 
this hormone, and further research is needed to verify the exact 
mechanisms of the decreased responsivity in these cases, and how 
this can be prevented (Krukier and Pogorelova, 2006) (Szukiewicz 
et. al. 2005).  
Relaxin
Relaxin is a peptide hormone that is considered to be similar to 
insulin. It is produced and secreted during pregnancy, at first by 
the corpus luteum in the ovary, and then later by the decidua, 
endometrium, and trophoblast of the placenta. Highest levels of 
relaxin are detectable in the first trimester of pregnancy. Then, 
levels tend to drop and stabilize. It mediates its effect both on 
the reproductive organs, as well as on other organs in the body 
(Dschietzig and Stangl, 2003).
This peptide hormone originally received its name due to its re-
laxing and elongating effects on the interpubic ligament. It further 
assists in softening the cervix and the tissues of the birth canal, 
thereby facilitating the passage of the fetus during parturition. This 
was later attributed to the ability of relaxin to reduce cervical col-
lagen concentration and increase collagen solubility during preg-
nancy. Estrogen was then found to further enhance these effects 
(Dschietzig and Stangl, 2003). 
As years went on, more research has been conducted to try to 
uncover some other important functions of this hormone. Relaxin 
has been found to have regulating effects on oxytocin secretion, 
although data is conflicting in regard to exactly how. Other effects 
of relaxin include its ability to inhibit uterine contractile activity 
throughout gestation. However, this effect has been found to be 
mild in humans. Relaxin also promotes the growth and differenti-
ation of the mammary parenchyma and stroma in preparation for 
lactation. It is further considered essential for the development of 
mammary nipples (Dschietzig and Stangl, 2003). 
Conclusion
The placenta is a transient organ that is formed during pregnancy 
for the purpose of nourishing the developing embryo/fetus and 
for maintaining an optimal physiological environment within the 
mother in order to sustain the pregnancy. During this approxi-
mately ninth month period, the placenta undergoes continuous 
growth and change in order to accommodate the ever changing 
needs of the mother and fetus. One of the major roles of this 
organ is its function as an endocrine unit with its release of many 
hormones which have widespread effects on the maternal tissues 
and organs. This is what allows the pregnancy to continue and 
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